Credit Suisse Ag Y M Abs Therapeutics, Inc. Call Options Transaction History
Credit Suisse Ag
- $101 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding YMAB
# of Institutions
106Shares Held
24.5MCall Options Held
40.3KPut Options Held
400-
Paradigm Biocapital Advisors LP New York, NY4.09MShares$45.5 Million1.93% of portfolio
-
Black Rock Inc. New York, NY2.94MShares$32.7 Million0.0% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA2.19MShares$24.4 Million2.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.04MShares$22.7 Million0.0% of portfolio
-
Polar Capital Holdings PLC London, X01.83MShares$20.4 Million0.15% of portfolio
About Y-mAbs Therapeutics, Inc.
- Ticker YMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,719,500
- Market Cap $487M
- Description
- Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...